Cameron Turtle

Insider Reports History

Entity
Individual
Location
C/O Eidos Therapeutics, Inc., 101 Montgomery Street, Suite 2550, San Francisco, CA
Signature
/s/ Paul Quinlan, as attorney-in-fact for Cameron Turtle
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Cameron Turtle:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Spyre Therapeutics, Inc. Chief Executive Officer, Director Common Stock 747K $530K $0.71 Feb 15, 2024 Direct
Oruka Therapeutics, Inc. Director Common Stock 85.2K $254K $2.98 Aug 29, 2024 By Turtle Family Trust
Spyre Therapeutics, Inc. Chief Executive Officer, Director Stock Option (Right to Buy) 278K Feb 1, 2024 Direct
Spyre Therapeutics, Inc. Chief Executive Officer, Director Series A Preferred Stock 0 Nov 24, 2023 Direct

Insider Reports Filed by Cameron Turtle

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ORKA Oruka Therapeutics, Inc. Aug 29, 2024 0 $0 3 Sep 6, 2024 Director
SYRE Spyre Therapeutics, Inc. Feb 15, 2024 1 $3.93K 4 Feb 20, 2024 Chief Executive Officer, Director
SYRE Spyre Therapeutics, Inc. Feb 1, 2024 1 $0 4 Feb 2, 2024 Chief Executive Officer, Director
AGLE Spyre Therapeutics, Inc. Nov 22, 2023 3 $0 4 Nov 27, 2023 Chief Executive Officer, Director
AGLE Aeglea BioTherapeutics, Inc. Jun 22, 2023 0 $0 3 Jun 30, 2023 Chief Operating Officer